EGFR and non-small cell lung carcinoma: By cell viability and colony formation assay we demonstrated that aprepitant potentiated the inhibitory effect of gefitinib/osimertinib in NSCLC cells (Fig. 8A and Supplementary Fig. S7A, B); interestingly, aprepitant showed no inhibitory effect on NSCLC cells proliferation in the presence or absence of gefitinib/osimertinib when EGFR expression was knocked down, suggesting a synergistical action between NK1R and EGFR (Fig. 8B).